MedTrace Logo

Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery

NCT00258297 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2013-10-16

No results posted yet for this study

Summary

RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gefitinib before surgery may shrink the tumor so that it can be removed.

PURPOSE: This phase II trial is studying how well gefitinib works in treating patients with stage I, stage II, or stage III esophageal cancer that can be removed by surgery.

Conditions

  • Esophageal Cancer

Interventions

DRUG

gefitinib

PROCEDURE

conventional surgery

PROCEDURE

enzyme inhibitor therapy

PROCEDURE

neoadjuvant therapy

PROCEDURE

protein tyrosine kinase inhibitor therapy

PROCEDURE

surgery

Sponsors & Collaborators

  • University of Rochester

    lead OTHER

Principal Investigators

  • Kishan J. Pandya, MD · James P. Wilmot Cancer Center

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-04-30
Primary Completion
2006-11-30
Completion
2006-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00258297 on ClinicalTrials.gov